download
print
% Change:
Volume:
52-Week High:
52-Week Low:

EVENTS & PRESENTATIONS

Alnylam Pharmaceuticals Conference Call to Discuss HELIOS-B Topline Results

Past Events ›

Alnylam Pharmaceuticals Q1 2024 Earnings Conference Call

Past Events ›

Alnylam Webcast from ACC to Discuss KARDIA-2 Phase 2 Results

Past Events ›

View all events and presentations ›
container-970 d-flex flex-1

2023 Annual Report

Download

2023 Corporate Responsibility Report

Download

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Quarterly Earnings Presentation - Icon

Q1 2024 Earnings Presentation VIEW PDF ›

10-K - Icon

Latest Form 10-K VIEW PDF ›

10-Q - Icon

Latest Form10-Q VIEW PDF ›

sec-icon

SEC
Filings VIEW All ›

sec-icon

2024 Proxy
Statement LEARN MORE ›

View all resources and documents ›

Discover Our Commitment to Patients, Employees, and Our Communities

Corporate Responsibility ›

PRESS RELEASES

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Learn More ›

Alnylam Issues 2023 Corporate Responsibility Report

Learn More ›

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Learn More ›

View all press releases ›